Achieve Absorbs FDA Setback as Spending Shifts Toward Launch
The company ended June with $187.3 million in cash and securities after a private placement.
Achieve Life Sciences (ACHV), a clinical-stage pharmaceutical company, received a Complete Response Letter that delayed the regulatory path for its smoking-cessation treatment cytisinicline.
The FDA issued the letter on June 20 after an inspection of Achieve’s prior manufacturer resulted in an Official Action Indicated classification. The agency tied its decision to manufacturing observations and unfinished labeling and identified no deficiencies involving clinical efficacy or safety.
Second-quarter net loss widened to $74.8 million from $12.7 million a year earlier, largely because of a $48.7 million noncash charge to remeasure warrant liabilities issued in a private placement. Operating expenses rose 46% to $18.4 million.
The composition of spending shifted toward corporate and commercial preparation. General and administrative expenses rose 149% to $14.6 million, while research and development expenses fell 43% to $3.8 million.
Achieve’s manufacturing transition advanced during the quarter. The company completed its analytical-method transfer to Adare, produced a first engineering batch and fully qualified testing procedures. Achieve plans to identify Adare as the commercial finished-product manufacturer in a fourth-quarter NDA resubmission.
The company now anticipates potential approval in the first half of 2027, with a U.S. launch to follow. Its previous timetable had called for a launch during that six-month period. Achieve also expanded its internal commercial operation by adding senior executives overseeing commercialization, sales, manufacturing and quality.
Long-term safety results covered 475 participants treated for as long as 52 weeks, up from an earlier update covering 334 participants who completed the one-year study. Median cumulative exposure was 361 days, and no new safety signals emerged.
The private placement provided $180 million upfront and could add $174 million through milestone-based warrants, giving Achieve financing for the resubmission and a conditional launch timetable now tied to resolving the FDA’s manufacturing concerns.